Incyte ZYNYZ — Total revenues increased by 30.4% to $41.39M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1275.6%, from $3.01M to $41.39M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful market penetration and growing demand for the therapy, while a decrease may signal competitive pressure or market saturation.
This metric represents the total gross revenue generated specifically from the commercial sales and licensing activities...
Similar to product-specific revenue reporting in other biopharmaceutical firms, this is comparable to individual drug franchise sales figures reported by peers.
incy_segment_zynyz_total_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $570.00K | $98.00K | $582.00K | $467.00K | $651.00K | $694.00K | $1.37M | $3.01M | $8.92M | $22.67M | $31.75M | $41.39M |
| QoQ Change | — | — | — | — | — | — | — | — | — | -82.8% | +493.9% | -19.8% | +39.4% | +6.6% | +97.8% | +119.2% | +196.5% | +154.2% | +40.0% | +30.4% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | +14.2% | +608.2% | +135.9% | +544.3% | >999% | >999% | >999% | >999% |